Lancet Diabetes Endocrinol: Dino sabutad combined cynacase treatment of primary parathyroid function

background !----: There are few treatments for parathyroidism in primary formthe purpose of this study is to assess the efficacy of denozumab (cinacalcet), a calcium-based agent, in the treatment of primary parathyroid functionmethod: This is a randomized, single-center, double-blind trial, recruiting patients over the age of 18 with primary parathyroid dysfunction, a random group (1:1:1), the combined group received Sinaxa 30 mg/day-dinosazumab 60 mg/6 months (sub-dermal injection);the main result was a change in bone density (BMD) at the far end of the lumbar spine, full hip joint, femur neck and forearm with a double X-ray bone density meter one year laterresults: March 14, 2017 - March 16, 2018, 285 participants were recruited, with 16, 15 and 15 patients in the combined group, the dinomonotag group and the placebo group, respectively, followed by one patient in the joint group who withdrew from the trialpatients with dino monoab therapy improved BMD compared to placebo: lumbar spine (joint group 5.4% (95% CI 2.7-8.1), Dinossad group 6.9% (95% CI 4.2-9.6) ;p.lt;0001), whole hip joint (5.0% -6.9, 4.1% ( 2.5-5.8) ;p , and femur neck (4.5% , 1.9-7.9, p0.0008; 3.8% , pThe BMD changes significantly at the far end of theforearmThere were a total of 6 non-lethal serious adverse events in(2 cases in the joint group, 1 case in the denosa nodagain group and 3 cases in the placebo group)There was no difference in the overall incidence of adverse events betweentreatment groups, and no fatal adverse eventsSummary: Studies have shown that denomatomatod can effectively improve BMD and bone conversion in patients with primary parathyroid function, regardless of whether or not they are treated with xenacase, and may be an effective choice for patients who do not want surgery